| Title |
Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development
|
|---|---|
| Published in |
Drug Design, Development and Therapy, May 2020
|
| DOI | 10.2147/dddt.s253232 |
| Pubmed ID | |
| Authors |
Brooke Benner, Logan Good, Dionisia Quiroga, Thomas E Schultz, Mahmoud Kassem, William E Carson, Mathew A Cherian, Sagar Sardesai, Robert Wesolowski |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 33% |
| Unknown | 2 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Scientists | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 115 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 115 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 18 | 16% |
| Student > Ph. D. Student | 13 | 11% |
| Researcher | 11 | 10% |
| Student > Master | 9 | 8% |
| Student > Doctoral Student | 6 | 5% |
| Other | 12 | 10% |
| Unknown | 46 | 40% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 14% |
| Biochemistry, Genetics and Molecular Biology | 11 | 10% |
| Agricultural and Biological Sciences | 8 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 7% |
| Neuroscience | 7 | 6% |
| Other | 16 | 14% |
| Unknown | 49 | 43% |
Attention Score in Context
This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 February 2024.
All research outputs
#2,451,873
of 25,387,668 outputs
Outputs from Drug Design, Development and Therapy
#129
of 2,268 outputs
Outputs of similar age
#64,751
of 410,102 outputs
Outputs of similar age from Drug Design, Development and Therapy
#3
of 43 outputs
Altmetric has tracked 25,387,668 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,268 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 410,102 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 43 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.